Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia

Trial Profile

Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine; Decitabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Interim results (n=54) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 26 Oct 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top